My Portfolio
+
LINK YOUR PORTFOLIO

Corvus Pharmaceuticals Inc CRVS:NASDAQ

RT Quote | Last NYSE Arca, VOL From CTA | USD
after hours iconAfter Hours: Last | 06/03/26 EDT
11.93quote price arrow up+0.33 (+2.84%)
Volume
37,121
Close
11.60quote price arrow down-0.09 (-0.77%)
Volume
1,552,186
52 week range
3.55 - 26.95
Loading...
  • Open11.76
  • Day High11.80
  • Day Low11.36
  • Prev Close11.60
  • 52 Week High26.95
  • 52 Week High Date01/23/26
  • 52 Week Low3.55
  • 52 Week Low Date06/23/25

Latest On Corvus Pharmaceuticals Inc

Key Stats

  • Market Cap975.449M
  • Shares Out84.09M
  • 10 Day Average Volume1.98M
  • Dividend-
  • Dividend Yield-
  • Beta0.85

Latest On Corvus Pharmaceuticals Inc

KEY STATS

  • Open11.76
  • Day High11.80
  • Day Low11.36
  • Prev Close11.60
  • 52 Week High26.95
  • 52 Week High Date01/23/26
  • 52 Week Low3.55
  • 52 Week Low Date06/23/25
  • Market Cap975.449M
  • Shares Out84.09M
  • 10 Day Average Volume1.98M
  • Dividend-
  • Dividend Yield-
  • Beta0.85

RATIOS/PROFITABILITY

  • EPS (TTM)-0.53
  • P/E (TTM)-21.81
  • Fwd P/E (NTM)-15.49
  • EBITDA (TTM)-47.814M
  • ROE (TTM)-30.46%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date08/05/2026(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Profile

MORE
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of ITK inhibition as a new approach to immunotherapy for a range of cancer and immune diseases. Its lead product candidate is soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. ITK, an enzyme that functions in...
Richard Miller M.D.
Chairman of the Board, President, Chief Executive Officer
Leiv Lea
Chief Financial Officer
Address
863 Mitten Rd Ste 102
Burlingame, CA
94010-1311
United States